



## Results of Annual General Meeting

**Sydney, 19 November 2024:** Innovative biotech company **Noxopharm Limited (ASX:NOX)** is pleased to announce the results of today's Annual General Meeting.

The results are set out in the attached document, in accordance with ASX Listing Rule 3.13.2 and Section 251AA(2) of the Corporations Act.

All resolutions were passed and decided by way of poll. In respect to Resolution 1 "Adoption of Remuneration Report", the resolution passed with in excess of 75% votes in favour of the resolution.

**-ENDS-**

### About Noxopharm

Noxopharm Limited (ASX:NOX) is an innovative Australian biotech company discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance mRNA vaccines.

The company utilises specialist in-house capabilities and strategic partnerships with leading researchers to build a growing pipeline of new proprietary drugs based on two technology platforms – Chroma™ (oncology) and Sofra™ (inflammation, autoimmunity, and mRNA vaccine enhancement).

Noxopharm also has a major shareholding in US registered, Australia based Nyrada Inc (ASX: NYR), a drug discovery and development company specialising in novel small molecule therapies.

To learn more, please visit: [noxopharm.com](http://noxopharm.com)

#### Investor, Corporate & Media enquiries:

Julian Elliott

M: 0425 840 071

E: [julian.elliott@noxopharm.com](mailto:julian.elliott@noxopharm.com)

#### Company Secretary:

David Franks

T: +61 2 8072 1400

E: [David.Franks@automicgroup.com.au](mailto:David.Franks@automicgroup.com.au)

*Dr Gisela Mautner, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.*

---

### Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.

# Disclosure of Proxy Votes

Noxopharm Limited

Annual General Meeting

Tuesday, 19 November 2024



Automic

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E [hello@automic.com.au](mailto:hello@automic.com.au)

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)			Results
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
1 Adoption of Remuneration Report	P	71,190,213	70,715,191 99.33%	378,212 0.53%	48,200	96,810 0.14%	72,236,251 99.48%	378,212 0.52%	959,600	-
2 Re-election of Mr Peter Marks as Director	P	71,943,464	71,789,154 99.79%	57,500 0.08%	194,949	96,810 0.13%	82,359,427 99.93%	57,500 0.07%	194,949	Carried
3 ASX Listing Rule 7.1A Approval of Future Issue of Securities	P	72,033,494	71,757,182 99.62%	170,502 0.24%	104,919	105,810 0.15%	81,425,055 98.69%	1,081,902 1.31%	104,919	Carried
4 Approval of Issue of Incentive Securities to Dr Gisela Mautner, Managing Director of the Company	P	36,830,351	35,076,294 95.24%	1,619,728 4.40%	35,308,062	134,329 0.36%	36,010,623 91.94%	3,155,378 8.06%	35,308,062	Carried
5 Approval of Issue of Convertible Notes and Unlisted Options	P	66,911,418	66,534,890 99.44%	240,518 0.36%	98,195	136,010 0.20%	76,232,963 99.69%	240,518 0.31%	1,009,595	Carried
6 Approval of Issue of Convertible Notes and Unlisted Options to 4F Investments Pty Limited, an Associated Entity to Mr Fred Bart, Director of the Company	P	72,127,248	71,619,372 99.30%	371,866 0.52%	11,165	136,010 0.19%	73,809,632 98.29%	1,283,266 1.71%	11,165	Carried

